Corporate Finance

Corporate acquisition

Due to economic recession and convectional pressure from the market situation , political weather implications and reducing interest rates from invested monies due to corporate weather problems , a need to address the impeding fiscal storm facing the company is ostensibly necessary . However the pressure from the share holders has applied pressure on an initiative that will propel the company situation to the corporate safe mode

Motive of the acquisition

The acquisition of UCB is based on the cyclical aspect and corporate structure of Biotech Corp . The cyclical aspect has

weighed heavily on the market value of Biotech share reducing capacity and prompting fiscal constrain on policy management based on essentials of the company 's financial capability . Peter G Hanson (1989 : Stress for success . The impeding storms of business insecurity [123]

Also high level competition for the market share of the existing products has constrained the sales pattern forcing a decreased sales rate and a closing the sales ambience window that leaves no choice but expansion and diversifying to other products like oncology and immunology is an open window . However the company liquidity is steadfast and the corporate structure permits countermeasures to overturn the cyclical aspect into an advantage . The overturn is on basis of affecting the market to have a different perception on Biotech . The supportive basis profoundly reflects on the interest rates which have reacted to the Biotech share negatively through decreased value . The decrease has significantly reduced the company equity and projected dividend plan value . As insulation against further plunge of the share value in the stock market , a policy to insulate the company from the market changes will obviously features all the contexts of acquisition . UCB has a global portfolio and has been making gains over the recent past with its acquisition of Schwartz pharmacy and rights royalties over patents . The acquisition of the pharmaceutical is weighing heavily on UCB liability value increasing the liability due to owning up to Schwartz debts . David J (2005 : Goldman intelligence : Business intelligence . Making acquisitions [Vol 35 , pp 13]

Acquiring UCB will manage the current performance crisis . It 's an ethical corporate decision which will overturn the cyclical situation Ethics and the implications of the ethical move will do well in the long-term in the meantime the high expenditure on the UCB acquisition is considerably too high and seemingly unnecessary defence against the impending fiscal storm ahead . According to the share markets , acquiring UCB will induce two perceptions to the clientele and investors . The impact of the acquisition will increase clientele-investor confidence on Biotech diverse abilities and financial portfolio . Secondly the acquisition will open the diversification window through using the acquisition to offset the products purchase price and subsequently increase customer numbers due to indication of the company 's products diversity

The essence of the acquisition will also manage sustenance of the current position of Biotech Corp as a market leader and integrate product dynamism meet the evolving customer needs . This means the company will be able to repose the...